Oakley Due Diligence Report
Why Begin with Due Diligence?
Many market entry programmes fail to achieve their commercial objectives—not because of regulatory issues, but because the fundamental commercial assumptions were never properly tested.
Oakley’s Due Diligence Report reduces uncertainty before substantial investment begins.
Our assessment enables you to:
Understand the commercial attractiveness of your product within UK and EU hospital markets.
Identify regulatory and technical gaps between your FDA ANDA and European requirements.
Evaluate manufacturing, technology transfer and supply chain implications.
Select the most appropriate regulatory pathway.
Estimate development timelines, costs and resource requirements.
Make an informed Go / No-Go decision before committing to the next stage of development.
A structured evaluation at the outset frequently saves months of unnecessary work and avoids significant expenditure on products that are unlikely to deliver an acceptable commercial return.
What Does the Assessment Cover?
Oakley’s Due Diligence methodology evaluates every UK market entry and European Market entry, opportunity across five integrated dimensions:
Regulatory Fit
Does your existing FDA ANDA align with MHRA and EMA regulatory expectations?
Commercial Viability
Is there a sufficiently attractive commercial opportunity to justify investment?
Manufacturing & Supply
Can the product be transferred, validated and manufactured successfully within Europe?
Filing Strategy
Should the programme begin with the UK, the EU or another regulatory pathway?
Execution Risk
What are the principal commercial, technical and regulatory risks, and how can they be mitigated?
The outcome is a structured recommendation that supports confident portfolio prioritisation and informed executive decision-making.
The objective is not simply to assess feasibility, but to provide senior management with the confidence to proceed—or the evidence to decide that resources are better invested elsewhere.
What You Receive
Every Due Diligence Report is written specifically for executive decision-making and concludes with practical, commercially focused recommendations.
Each Oakley Due Diligence Report is tailored to the individual product but typically includes:
Executive Summary
Commercial Opportunity Assessment
Regulatory Gap Analysis
Reference Product Review
Manufacturing & Technology Transfer Assessment
Market Entry Strategy Options
Development Track Recommendation
Estimated Development Timeline
High-Level Cost Assessment
Commercial Risk Assessment
Recommended Next Steps
The Due Diligence Report is written for executive decision-makers and is intended to support internal investment discussions, strategic planning and project approval.
What You Receive
Every Due Diligence Report is written specifically for executive decision-making and concludes with practical, commercially focused recommendations.
Each Oakley Due Diligence Report is tailored to the individual product but typically includes:
Executive Summary
Commercial Opportunity Assessment
Regulatory Gap Analysis
Reference Product Review
Manufacturing & Technology Transfer Assessment
Market Entry Strategy Options
Development Track Recommendation
Estimated Development Timeline
High-Level Cost Assessment
Commercial Risk Assessment
Recommended Next Steps
The Due Diligence Report is written for executive decision-makers and is intended to support internal investment discussions, strategic planning and project approval.
Who Is This Service Designed For?
The Oakley Due Diligence Offering is particularly suited to organisations that:
Hold one or more FDA-approved sterile injectable ANDAs.
Are evaluating expansion into UK or European markets.
Require an independent commercial assessment before committing internal resources.
Need objective portfolio prioritisation.
Are considering licensing, partnership or acquisition opportunities.
Wish to reduce development risk before commencing regulatory activities.
Whether evaluating a single product or an entire portfolio, Oakley’s methodology provides a structured framework for making better commercial decisions.
Typical Project Timeline
Most Due Diligence projects are completed within three to four weeks, depending upon product complexity and the availability of supporting documentation.
The typical programme comprises:
Time elapsed project duration 3-4 weeks
Stage
Initial Discovery Meeting
Information Collection
Technical & Commercial Assessment
Report Preparation
Presentation & Recommendations
Typical Duration
1 hour
3–5 days
2–3 weeks
3–5 days
1–2 hours
Why Oakley?
Oakley combines more than thirty years of international pharmaceutical development experience with practical expertise in sterile injectable products, technology transfer, regulatory strategy and commercial market entry.
Unlike organisations that focus solely on regulatory submissions or technical consultancy, Oakley integrates commercial, regulatory and operational considerations into a single structured assessment that combines Commercial Due Diligence with technical and regulatory assessment for UK Market Entry and European Market Entry.
Our objective is not simply to determine whether market entry is technically possible.
It is to determine whether it represents the right commercial decision for your business.
Download the Oakley Due Diligence Report Overview (PDF)
If you would like a concise summary of the Oakley Due Diligence Offering, you can download our two-page overview.
Frequently Asked Questions
-
Because commercial viability should be established before significant investment is committed. Early assessment frequently identifies opportunities, constraints and alternative strategies that can substantially improve project outcomes.
-
Typically we request your FDA ANDA documentation, product overview, manufacturing information and commercial objectives. A detailed information request is agreed during the Discovery Meeting.
-
Most projects are completed within three to four weeks following receipt of the required documentation.
-
The report concludes with practical recommendations and, where appropriate, a proposed Market Entry strategy. You remain entirely free to decide how those recommendations are implemented.
-
No.
The Due Diligence Report is an independent advisory service. Many clients choose to continue with Oakley because we can also support technology transfer, regulatory strategy and commercial implementation, but there is no obligation to do so.
Every successful UK or EU Market Entry programme starts with an informed decision.
Oakley’s Due Diligence Offering provides the structured commercial and technical insight needed to determine whether your FDA-approved ANDA represents the right opportunity—and, if so, the most appropriate path forward.
Arrange a confidential Discovery Meeting to discuss your portfolio and determine whether an Oakley Due Diligence Report could support your UK or EU expansion strategy.